This study aimed to compare and evaluate the efficacy of the blood pressure (BP) control and cholesterol-lowering effects and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe versus rosuvastatin and ezetimibe double therapy or telmisartan single therapy in dyslipidemia patients with hypertension. After a wash-out/therapeutic lifestyle change period of ≥4 weeks, a total of 100 eligible patients were randomized and received one of three treatments for 8 weeks: (1) telmisartan 80 mg/rosuvastatin 20 mg/ezetimibe 10 mg (TRE), (2) rosuvastatin 20 mg/ezetimibe 10 mg (RE), or (3) telmisartan 80 mg (T). The primary endpoint was the efficacy evaluation of TRE by comparing changes in mean sitting systolic blood pressure (msSBP) and mean percentage change in low-density lipoprotein-C (LDL-C) from baseline after 8 weeks of treatment.

中文翻译：

---

替米沙坦、瑞舒伐他汀和依折麦布联合治疗血脂异常和高血压患者的疗效和安全性：一项随机、双盲、多中心、治疗验证性 III 期临床试验

本研究旨在比较和评估替米沙坦、瑞舒伐他汀和依折麦布联合治疗与瑞舒伐他汀和依折麦贝双联治疗或替米沙坦单药治疗对血脂异常合并高血压患者的血压（BP）控制和降胆固醇效果以及安全性。经过≥4周的清除/治疗生活方式改变期后，总共100名符合条件的患者被随机分配并接受三种治疗方法之一，为期8周：（1）替米沙坦80毫克/瑞舒伐他汀20毫克/依折麦布10毫克（TRE） ，(2) 瑞舒伐他汀 20 mg/依折麦布 10 mg (RE)，或 (3) 替米沙坦 80 mg (T)。主要终点是通过比较治疗 8 周后平均坐位收缩压 (msSBP) 的变化和低密度脂蛋白 -C (LDL-C) 相对于基线的平均百分比变化来评估 TRE 的疗效。